LQDA
Liquidia Corporation
9.91
+
0.13
1.33%
1 x 9.90
1 x 9.96
bid
ask
1 @ 04:00 PM
9.91+0.00 (0.00%)
Bearish
4
Bullish
9
sentiment
9.68
day range
10.07
5.71
52 week range
16.99
News
...
Profile
...
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-05 | 2024-09 | -0.38 | N/A | N/A | N/A |
2024-08-07 | 2024-06 | -0.35 | -0.37 | -0.02 | -5.71% |
2024-05-13 | 2024-03 | -0.32 | -0.54 | -0.22 | -68.75% |
2024-05-13 | 2024-03 | -0.32 | N/A | N/A | N/A |
2024-03-13 | 2023-12 | -0.23 | N/A | N/A | N/A |
2024-03-13 | 2023-12 | -0.23 | -0.42 | -0.19 | -82.61% |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-13 | Wedbush | Upgrade | Underperform | Underperform |
2023-08-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-09 | Needham | Upgrade | Buy | Buy |
2023-07-30 | Needham | Upgrade | Buy | Buy |
2023-07-24 | Needham | Upgrade | Buy | Buy |
2023-06-29 | Wedbush | Upgrade | Underperform |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-09-02 | ADAIR JASON | Officer | 115.81K | Sale |
2024-09-11 | CALIGAN PARTNERS L,P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Stock Award(Grant) |
2024-06-19 | HOROBIN JOANNA C | Director | 20.36K | Stock Award(Grant) |
2024-07-11 | JEFFS ROGER A | Chief Executive Officer | 2.41M | Sale |
2024-09-02 | KASETA MICHAEL | Chief Operating Officer | 314.97K | Sale |
2024-06-19 | KIRSCH ARTHUR S | Director | 52.36K | Stock Award(Grant) |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Caligan Partners, LP | 9.24M | 72.56M | 14.28% |
2023-06-29 | Blackrock Inc. | 3.29M | 25.85M | 5.09% |
2023-06-29 | Vanguard Group Inc | 2.75M | 21.57M | 4.24% |
2023-06-29 | Kynam Capital Management, LP | 1.64M | 12.89M | 2.54% |
2023-06-29 | State Street Corporation | 1.04M | 8.20M | 1.61% |
2023-06-29 | Geode Capital Management, LLC | 954.52K | 7.49M | 1.47% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 1.53M | 12.02M | 2.37% |
2023-08-30 | iShares Russell 2000 ETF | 1.10M | 7.53M | 1.69% |
2023-06-29 | Vanguard Extended Market Index Fund | 705.02K | 5.53M | 1.09% |
2023-07-30 | Fidelity Small Cap Index Fund | 429.77K | 3.32M | 0.66% |
2023-08-30 | Invesco ETF Tr II-Invesco DWA Small Cap Momentum ETF | 287.54K | 1.98M | 0.44% |
2023-08-30 | iShares Russell 2000 Growth ETF | 275.29K | 1.89M | 0.43% |
This topic has been deleted. Only users with topic management privileges can see it.
-
-
-
$LQDA looking damn fine pre market. Looking like a able stock today
-
$OBSV Analysts expect $16-$36 per share.
Shareholders will be ecstatic, with their stake up 30% over the past week following ObsEva SA‘s (NASDAQ:OBSV) latest quarterly results. Revenues came in 113% better than analyst models expected, at US$4.0kwhile statutory losses per share were US$0.48, in line with forecasts. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
-
Liquidia Corp faces renewed legal challenge from United Therapeutics
news.google.com • -
Liquidia (NASDAQ:LQDA) Shares Gap Up to $10.00
news.google.com • -
Liquidia Corp [LQDA] Investment Guide: What You Need to Know
news.google.com • -
A stock that deserves closer examination: Liquidia Corp (LQDA)
news.google.com •